Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 7/20 | 0.64 |
| ▸ | HSD17B1 | P14061 | 3/20 | 0.63 |
| ▸ | HSD17B2 | P37059 | 3/20 | 0.63 |
| ▸ | GFER | P55789 | 1/20 | 0.59 |
| ▸ | FYN | P06241 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | ESR1 | P03372 | 1/20 | 0.53 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1135975 | 0.87 | ERN1 (0.60) | ERN1HSD17B1HSD17B2MEN1KMT2A | |
| SCHEMBL30283775 | 0.87 | ERN1 (0.60) | ERN1HSD17B1HSD17B2MEN1KMT2A | |
| SCHEMBL17795214 | 0.86 | ERN1 (0.60) | ERN1HSD17B1HSD17B2GFERPDK2 | |
| Hydrochloric Acid SCHEMBL28646857 | 0.86 | ERN1 (0.59) | ERN1HSD17B1HSD17B2MEN1KMT2A | |
| SCHEMBL12168605 | 0.85 | ERN1 (0.58) | ERN1PDK2LMNAHDAC6 | |
| SCHEMBL18317091 | 0.83 | HSD17B1 (0.67) | ERN1HSD17B1HSD17B2PDK2 | |
| SCHEMBL19369002 | 0.82 | ERN1 (0.56) | ERN1HSD17B1HSD17B2FYNPDK2 | |
| SCHEMBL20057645 | 0.82 | HPGD (0.72) | ERN1HSD17B2GFERFYNMEN1 | |
| SCHEMBL20246484 | 0.82 | ERN1 (0.56) | ERN1HSD17B1HSD17B2GFERFYN | |
| SCHEMBL19567237 | 0.82 | ERN1 (0.56) | ERN1HSD17B1HSD17B2PDK2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11673867-B2 | Sulfonamide derivative or pharmaceutically acceptable acid-addition salt | UNIVERSITY OF TSUKUBA (JP) | 2023-06-13 | — | — | US | disclosed |
| US-11673867-B2 | Sulfonamide derivative or pharmaceutically acceptable acid-addition salt | UNIVERSITY OF TSUKUBA (JP) | 2023-06-13 | — | — | US | disclosed |
| EP-3725780-B1 | SULFONAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE ACID-ADDITION SALT | UNIV TSUKUBA (JP) | 2023-03-01 | — | — | EP | disclosed |
| US-20210078955-A1 | SULFONAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE ACID-ADDITION SALT | UNIVERSITY OF TSUKUBA (JP) | 2021-03-18 | — | — | US | disclosed |
| US-20210078955-A1 | SULFONAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE ACID-ADDITION SALT | UNIVERSITY OF TSUKUBA (JP) | 2021-03-18 | — | — | US | disclosed |
| EP-3725780-A1 | SULFONAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE ACID-ADDITION SALT | University of Tsukuba (JP) | 2020-10-21 | — | — | EP | disclosed |
| US-10351522-B2 | Sulfonamide derivative and pharmaceutically acceptable acid addition salt thereof | UNIVERSITY OF TSUKUBA (JP) | 2019-07-16 | — | — | US | disclosed |
| US-10351522-B2 | Sulfonamide derivative and pharmaceutically acceptable acid addition salt thereof | UNIVERSITY OF TSUKUBA (JP) | 2019-07-16 | — | — | US | disclosed |
| US-20180179151-A1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF | UNIVERSITY OF TSUKUBA (JP) | 2018-06-28 | — | — | US | disclosed |
| US-20180179151-A1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF | UNIVERSITY OF TSUKUBA (JP) | 2018-06-28 | — | — | US | disclosed |
| US-20180179151-A1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF | UNIVERSITY OF TSUKUBA (JP) | 2018-06-28 | — | — | US | disclosed |
| EP-3309146-A1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF | University of Tsukuba (JP) | 2018-04-18 | — | — | EP | disclosed |
| EP-3309146-A1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF | University of Tsukuba (JP) | 2018-04-18 | — | — | EP | disclosed |
| WO-2016199906-A1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF | 国立大学法人筑波大学 | 2016-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180179151-A1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF | HCRTR2, HCRTR1, NPSR1 | ERN1 4175/4885HSD17B1 990/4885HSD17B2 935/4885 |
| US-11673867-B2 | Sulfonamide derivative or pharmaceutically acceptable acid-addition salt | HCRTR2, HCRTR1, NPSR1 | ERN1 4183/4885HSD17B1 962/4885HSD17B2 887/4885 |
| US-10351522-B2 | Sulfonamide derivative and pharmaceutically acceptable acid addition salt thereof | HCRTR2, HCRTR1, NPSR1 | ERN1 4175/4885HSD17B1 990/4885HSD17B2 935/4885 |
| US-20210078955-A1 | SULFONAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE ACID-ADDITION SALT | HCRTR2, HCRTR1, NPSR1 | ERN1 4183/4885HSD17B1 962/4885HSD17B2 887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.